{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:22:33Z","timestamp":1763806953654},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We report our experience using rapamycin in patients with Wegener\u2019s granulomatosis (WG) who failed to achieve remission with conventional treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four patients treated with rapamycin sustained remissions of at least 6 months\u2019 duration while receiving prednisone \u2264 10 mg\/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.080664","type":"journal-article","created":{"date-parts":[[2008,11,14]],"date-time":"2008-11-14T17:12:38Z","timestamp":1226682758000},"page":"116-119","source":"Crossref","is-referenced-by-count":6,"title":["Limited Utility of Rapamycin in Severe, Refractory Wegener\u2019s Granulomatosis"],"prefix":"10.3899","volume":"36","author":[{"given":"CURRY L.","family":"KOENING","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JOS\u00c9","family":"HERN\u00c1NDEZ-RODR\u00cdGUEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EAMONN S.","family":"MOLLOY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TIFFANY M.","family":"CLARK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GARY S.","family":"HOFFMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,1,1]]},"reference":[{"key":"2018112909180218000_36.1.116.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390112"},{"key":"2018112909180218000_36.1.116.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5091.265"},{"key":"2018112909180218000_36.1.116.3","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E"},{"key":"2018112909180218000_36.1.116.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020286"},{"key":"2018112909180218000_36.1.116.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21142"},{"key":"2018112909180218000_36.1.116.6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-6-488"},{"key":"2018112909180218000_36.1.116.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041884"},{"key":"2018112909180218000_36.1.116.8","doi-asserted-by":"crossref","unstructured":"Sehgal SN . Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35 Suppl:7\u201314.","DOI":"10.1016\/S0041-1345(03)00211-2"},{"key":"2018112909180218000_36.1.116.9","doi-asserted-by":"crossref","first-page":"22737","DOI":"10.1016\/S0021-9258(18)41589-X","article-title":"Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes","volume":"268","author":"Morice","year":"1993","journal-title":"J Biol Chem"},{"key":"2018112909180218000_36.1.116.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-7-200604040-00009"},{"key":"2018112909180218000_36.1.116.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000258586.52777.4c"},{"key":"2018112909180218000_36.1.116.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000136812.90177.94"},{"key":"2018112909180218000_36.1.116.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70434-3"},{"key":"2018112909180218000_36.1.116.14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2249.1993.tb05918.x","article-title":"Serum markers of T cell activation in relapses of Wegener\u2019s granulomatosis","volume":"91","author":"Stegeman","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"2018112909180218000_36.1.116.15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.080664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T02:51:10Z","timestamp":1632192670000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.080664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.3899\/jrheum.080664"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.080664","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}